IMR Press / CEOG / Volume 11 / Issue 1-2 / pii/1634257806312-2146792654

Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 47 Issue 1 (2020). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Original Research
Testosterone, 17 Ks, l7βE2 FSH-LH variations and hirsutism modifications during spironolactone therapy
Show Less
1 Clinical Medicine Institute, Padua University (Italy)
2 Obstetric and Gynecologic Clinic, Padua University (Italy)
Clin. Exp. Obstet. Gynecol. 1984, 11(1-2), 49–54;
Published: 10 March 1984
Abstract

The research here reported concerns 9 hirsute women, four of them with PCO and five with idiopathic hirsutism, who underwent treatment with spironolactone. 4 non hirsute hypertensive cases served as control. For one year hair growth, testosterone, 17 Ks, estradiol and gonadotropins behaviours were studied in all of the patients. Results clearly show that the peripherical response (the hair) to the therapy is only just sufficient, and corresponds to a good reduction of the androgenic hormones in blood. However, there is also an LH gonadotropin secretion reduction which is statistically scarcely significant. If the therapeutic response of hair were good, fetal risk could be prevented with safe and contemporaneous contraception. However, since the response is scarcely sufficient, we do not think this therapy is more advisable than other ones.
Share
Back to top